|Articles|October 12, 2020
Assessing Multiple Critical Quality Attributes of Monoclonal Antibody and Comparability Assessments
Author(s)Agilent Technologies
Discover how LC/MS peptide mapping can be used to characterize and quantify different monoclonal antibody (mAb) critical quality attributes (CQAs).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5